Peripheral Neuropathy Medical Slides
Generate publication-quality peripheral neuropathy lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Peripheral Neuropathy DeckWhy teach Peripheral Neuropathy?
Peripheral neuropathy affects an estimated 2-3% of the general population, rising to 8% in adults over 55. Diabetic neuropathy is the most common cause in developed countries, while a systematic evaluation identifies treatable etiologies in up to 75% of cases. Teaching peripheral neuropathy requires a pattern-based diagnostic approach correlating clinical phenotype with electrodiagnostic findings to guide targeted investigation and treatment.
What AI generates for Peripheral Neuropathy
Enter “Peripheral Neuropathy” and SlideCraft generates a complete lecture deck with slides like these.
See it in action
Type any medical topic and watch AI generate a presentation slide in seconds. No signup required.
3 free previews per hour · No account needed
Enter a topic and click Generate to see your AI slide
Peripheral Neuropathy Presentation FAQ
How should the electrodiagnostic pattern approach be taught?
Present the key NCS patterns that narrow the differential: (1) uniform demyelination (slow velocities, prolonged distal latencies in all nerves) suggests hereditary neuropathy (CMT1A), (2) multifocal demyelination with conduction block suggests CIDP or MMN, (3) length-dependent axonal loss (reduced amplitudes, normal velocities) suggests metabolic/toxic causes, (4) asymmetric axonal loss suggests vasculitic neuropathy. This pattern recognition approach converts a broad differential into focused testing.
What workup algorithm should be presented for undifferentiated neuropathy?
Present a tiered approach: Tier 1 (all patients): glucose/HbA1c, B12 with methylmalonic acid, TSH, CBC, CMP, SPEP/UPEP with immunofixation. Tier 2 (if Tier 1 negative): ANA, ESR/CRP, hepatitis B/C, HIV, ACE level, antigliadin antibodies, heavy metals. Tier 3 (targeted): anti-MAG antibody, ganglioside antibodies (anti-GM1 for MMN), genetic testing for CMT, nerve biopsy for vasculitis. This systematic approach identifies a treatable cause in 50-75% of cases.
How should neuropathic pain pharmacotherapy be presented?
Present the evidence-based hierarchy per the 2017 NeuPSIG guidelines: first-line (TCAs — amitriptyline/nortriptyline, SNRIs — duloxetine/venlafaxine, gabapentinoids — gabapentin/pregabalin), second-line (tramadol, capsaicin 8% patch, lidocaine patch for focal pain), third-line (strong opioids as last resort). Emphasize NNT values: duloxetine NNT 6.4, pregabalin NNT 7.7, gabapentin NNT 6.3 — highlighting that most patients require combination therapy for adequate relief.
Simple pricing, no surprises
Start free today. Upgrade when your department needs more.
Free
Try SlideCraft with no commitment
- 2 decks per month
- AI slides with speaker notes
- View & present only (no export)
- 7-day cloud storage
- Slide Checker & Outline Generator
Pro
For clinicians who lecture weekly
- 10 decks/mo + $2.50/extra
- AI Critic Mode (5-axis review)
- Document-to-deck (PDF upload)
- PDF, PPTX, SCORM & image export
- Permanent cloud storage
Expert
For academic physicians who publish and present
- 25 decks/mo + $2.00/extra
- PubMed source verification
- Paper-to-deck pipeline
- Auto-citations (Vancouver)
- Everything in Pro